Professor Kang Hyung-jin of Seoul National University Hospital elected the next chairman of the Korean Blood Society...Production of CART treatment in Korea's first hospital
Nov 13, 2025
Kang Hyung-jin, a professor of pediatrics at Seoul National University Hospital, was elected as the 17th chairman of the board at the 66th Fall Conference of the Korean Blood Society on the 7th. Professor Kang's term is two years from July 2026.
The Korean Hematology Association is a leading hematology academic organization established in 1958 and is widely participated by experts in various clinical departments such as internal medicine, pediatrics, and diagnostic laboratory medicine, as well as basic medicine such as immunology and genomics.
The conference holds the International Congress of Korean Society of Hematology (ICKSH) every year, and runs 14 research conferences, including the Precision Medical Research Association and the Blood Cancer Big Data Research Association, playing a central role in hematology research and academic exchanges in Korea.
Professor Kang is a professor at the School of Pediatrics at Seoul National University, and he treats patients with childhood leukemia and childhood cancer in the Department of Pediatrics and Adolescents at Seoul National University Hospital. He is an international expert who has achieved a number of clinical achievements in the field of childhood leukemia and hematopoietic stem cell transplantation, and has led innovative achievements by producing CAR-T treatments directly in hospitals for the first time in Korea to successfully treat leukemia patients. Based on these research results, it leads clinical research and multi-center collaborative research to improve the survival rate and quality of life of pediatric cancer patients, and is also striving to expand the clinical application of next-generation cell and gene therapy.
In addition, he served as an academic director of the Korean Society of Pediatric Hematopoietic Oncology, chairman of the Cell Immunotherapy Committee of the Korean Society of Hematopoietic Cell Transplantation, vice chairman of the Korean Society of Immunocyte Genetic Therapy, and chairman of the Pediatric Lymphocyte Leukemia Research Council, contributing to the development of hematologic oncology and cell gene therapy in Korea, the establishment of research infrastructure, and the revitalization of international academic exchanges.
Kang Hyung-jin, the next chairman of the board, said "In the era of global AI, we will warmly communicate with the members of the society as well as the government and the public and draw the future of hematology together amid changes that open up new diagnostic and treatment horizons.""The society will play a central role in ensuring that academic achievements can lead to the development of patient treatment." he said.
The Korean Hematology Association is a leading hematology academic organization established in 1958 and is widely participated by experts in various clinical departments such as internal medicine, pediatrics, and diagnostic laboratory medicine, as well as basic medicine such as immunology and genomics.
The conference holds the International Congress of Korean Society of Hematology (ICKSH) every year, and runs 14 research conferences, including the Precision Medical Research Association and the Blood Cancer Big Data Research Association, playing a central role in hematology research and academic exchanges in Korea.
Professor Kang is a professor at the School of Pediatrics at Seoul National University, and he treats patients with childhood leukemia and childhood cancer in the Department of Pediatrics and Adolescents at Seoul National University Hospital. He is an international expert who has achieved a number of clinical achievements in the field of childhood leukemia and hematopoietic stem cell transplantation, and has led innovative achievements by producing CAR-T treatments directly in hospitals for the first time in Korea to successfully treat leukemia patients. Based on these research results, it leads clinical research and multi-center collaborative research to improve the survival rate and quality of life of pediatric cancer patients, and is also striving to expand the clinical application of next-generation cell and gene therapy.
In addition, he served as an academic director of the Korean Society of Pediatric Hematopoietic Oncology, chairman of the Cell Immunotherapy Committee of the Korean Society of Hematopoietic Cell Transplantation, vice chairman of the Korean Society of Immunocyte Genetic Therapy, and chairman of the Pediatric Lymphocyte Leukemia Research Council, contributing to the development of hematologic oncology and cell gene therapy in Korea, the establishment of research infrastructure, and the revitalization of international academic exchanges.
Kang Hyung-jin, the next chairman of the board, said "In the era of global AI, we will warmly communicate with the members of the society as well as the government and the public and draw the future of hematology together amid changes that open up new diagnostic and treatment horizons.""The society will play a central role in ensuring that academic achievements can lead to the development of patient treatment." he said.
|
This article was translated by Naver AI translator.
